MCID: DXR001
MIFTS: 40

Doxorubicin Induced Cardiomyopathy

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

MalaCards integrated aliases for Doxorubicin Induced Cardiomyopathy:

Name: Doxorubicin Induced Cardiomyopathy 49

Classifications:



Summaries for Doxorubicin Induced Cardiomyopathy

MalaCards based summary : Doxorubicin Induced Cardiomyopathy is related to pulmonary blastoma and deafness, autosomal recessive 39. An important gene associated with Doxorubicin Induced Cardiomyopathy is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include heart, bone marrow and bone, and related phenotypes are Decreased cell migration and Decreased substrate adherent cell growth

Related Diseases for Doxorubicin Induced Cardiomyopathy

Graphical network of the top 20 diseases related to Doxorubicin Induced Cardiomyopathy:



Diseases related to Doxorubicin Induced Cardiomyopathy

Symptoms & Phenotypes for Doxorubicin Induced Cardiomyopathy

GenomeRNAi Phenotypes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.56 EGFR EPHB2 MAPK14 MET
2 Decreased substrate adherent cell growth GR00193-A-2 9.33 EGFR EPHB2 MAPK14
3 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 8.96 MAPK14 MET
4 Increased cell viability after pRB stimulation GR00230-A-1 8.8 EGFR MAPK14 MET

MGI Mouse Phenotypes related to Doxorubicin Induced Cardiomyopathy:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.15 MET CNR1 DES EGFR EPHB2 EPOR
2 cardiovascular system MP:0005385 10.11 DES ECE1 EGFR EPOR GATA4 HGF
3 growth/size/body region MP:0005378 10.09 CNR1 ECE1 EGFR EPHB2 EPOR GATA4
4 mortality/aging MP:0010768 10.02 CNR1 DES ECE1 EGFR EPHB2 EPOR
5 embryo MP:0005380 10 ECE1 EGFR EPOR GATA4 HGF MAPK14
6 digestive/alimentary MP:0005381 9.95 CNR1 ECE1 EGFR EPHB2 GATA4 MET
7 integument MP:0010771 9.88 CNR1 CSF3 ECE1 EGFR GATA4 MAPK14
8 liver/biliary system MP:0005370 9.85 EGFR EPOR GATA4 HGF MAPK14 MET
9 nervous system MP:0003631 9.76 CNR1 ECE1 EGFR EPHB2 EPOR GATA4
10 muscle MP:0005369 9.73 MAPK14 MET DES ECE1 EGFR GATA4
11 no phenotypic analysis MP:0003012 9.43 CNR1 EGFR EPOR GATA4 HGF MET
12 normal MP:0002873 9.17 GATA4 MAPK14 MET CNR1 ECE1 EGFR

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

Drugs for Doxorubicin Induced Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
2
Doxil Approved June 1999 Phase 2, Phase 3 31703
3 Topoisomerase Inhibitors Phase 2, Phase 3
4 Anti-Bacterial Agents Phase 2, Phase 3
5 Antibiotics, Antitubercular Phase 2, Phase 3
6
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
7
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
8 Albumin-Bound Paclitaxel Phase 2
9
Menthol Approved 2216-51-5 16666
10 Chelating Agents
11 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients Unknown status NCT02078388 Phase 2, Phase 3 Doxorubicin
2 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer Recruiting NCT02677714 Phase 2
3 Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients Completed NCT03000036 Doxorubicin;Gadoterate Meglumine
4 Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy Recruiting NCT02796365

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

Anatomical Context for Doxorubicin Induced Cardiomyopathy

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

38
Heart, Bone Marrow, Bone, Pituitary, Endothelial, Testes, Myeloid

Publications for Doxorubicin Induced Cardiomyopathy

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50) (show all 145)
# Title Authors Year
1
Ability of Nonstrain Diastolic Parameters to Predict Doxorubicin-Induced Cardiomyopathy: A Systematic Review With Meta-Analysis. ( 29045286 )
2018
2
Embryonic stem cell-derived cardiomyocytes for the treatment of doxorubicin-induced cardiomyopathy. ( 29402309 )
2018
3
Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. ( 29074412 )
2018
4
Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium. ( 29146241 )
2018
5
Correction to: "Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy." ( 28087848 )
2017
6
Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy. ( 28662206 )
2017
7
Expression of Flk-1 and Cyclin D2 mRNA in the Myocardium of Rats with Doxorubicin-Induced Cardiomyopathy and after Treatment with Betulonic Acid Amide. ( 29063324 )
2017
8
Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. ( 28423723 )
2017
9
Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction. ( 29026304 )
2017
10
Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes. ( 28153388 )
2017
11
Mechanistic clues to the protective effect of chrysin against doxorubicin-induced cardiomyopathy: Plausible roles of p53, MAPK and AKT pathways. ( 28684738 )
2017
12
Vitamin C mitigates oxidative/nitrosative stress and inflammation in Doxorubicin-induced cardiomyopathy. ( 28710069 )
2017
13
Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats. ( 28445944 )
2017
14
Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase. ( 28608983 )
2017
15
Protective effect of Co-enzyme Q10 On doxorubicin-induced cardiomyopathy of rat hearts. ( 27087047 )
2016
16
Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. ( 26873966 )
2016
17
Sarco"MiR" friend or foe: a perspective on the mechanisms of doxorubicin-induced cardiomyopathy. ( 27294099 )
2016
18
Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice. ( 27167338 )
2016
19
Obestatin attenuated doxorubicin-induced cardiomyopathy via enhancing long noncoding Mhrt RNA expression. ( 27261628 )
2016
20
Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy. ( 26057572 )
2015
21
Astragalus polysaccharide improves cardiac function in doxorubicin-induced cardiomyopathy through ROS-p38 signaling. ( 26885153 )
2015
22
Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. ( 25660617 )
2015
23
A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment. ( 25938766 )
2015
24
Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats. ( 25590792 )
2015
25
Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment. ( 26075032 )
2015
26
Shengmai injection improved Doxorubicin-induced cardiomyopathy by alleviating myocardial endoplasmic reticulum stress and caspase-12 dependent apoptosis. ( 25839043 )
2015
27
Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. ( 25569804 )
2015
28
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. ( 26191652 )
2015
29
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. ( 26511374 )
2015
30
Heart rate dynamics in doxorubicin-induced cardiomyopathy. ( 25798626 )
2015
31
Arginase inhibition augments nitric oxide production and facilitates left ventricular systolic function in doxorubicin-induced cardiomyopathy in mice. ( 25263201 )
2014
32
Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals. ( 25298583 )
2014
33
Embryonic Stem Cells and Released Factors Stimulate c-kit (+ve) /FLK-1(+ve) Progenitor Cells and Promote Neovascularization in Doxorubicin-induced Cardiomyopathy. ( 24593859 )
2014
34
Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. ( 24486195 )
2014
35
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. ( 25504881 )
2014
36
Therapeutic use of H2O2-responsive anti-oxidant polymer nanoparticles for doxorubicin-induced cardiomyopathy. ( 24767791 )
2014
37
Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy. ( 24244825 )
2013
38
Macrophage migration inhibitory factor deficiency augments doxorubicin-induced cardiomyopathy. ( 24334905 )
2013
39
Manipulation of Cardiac PI3K/Akt Signaling by Apoptosis regulator through modulating IAP expression (ARIA) Regulates Cardiomyocyte Death during the Doxorubicin-induced Cardiomyopathy. ( 24338479 )
2013
40
The beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. ( 23731918 )
2013
41
Effects of Histidine and N-Acetylcysteine on Doxorubicin-Induced Cardiomyopathy in Rats. ( 24343415 )
2013
42
Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat. ( 23741376 )
2013
43
Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. ( 24228260 )
2013
44
Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. ( 22719160 )
2012
45
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. ( 22465037 )
2012
46
Discordant impairment of multidirectional myocardial deformation in rats with Doxorubicin induced cardiomyopathy. ( 22486544 )
2012
47
Effects of the antioxidant agent tempol on periapical lesions in rats with doxorubicin-induced cardiomyopathy. ( 22244634 )
2012
48
Fosinopril attenuates the doxorubicin-induced cardiomyopathy by restoring the function of sarcoplasmic reticulum. ( 22729889 )
2012
49
Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. ( 22808256 )
2012
50
Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. ( 22449713 )
2012

Variations for Doxorubicin Induced Cardiomyopathy

Expression for Doxorubicin Induced Cardiomyopathy

Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for Doxorubicin Induced Cardiomyopathy

Pathways related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 CSF3 EGFR EPHB2 EPOR HGF MAPK14
2
Show member pathways
13.48 EGFR EPHB2 EPOR GATA4 HGF MAPK14
3
Show member pathways
13.36 EGFR EPHB2 EPOR HGF MAPK14 MET
4
Show member pathways
13.34 EGFR EPHB2 EPOR HGF MAPK14 MET
5
Show member pathways
13.14 EGFR EPHB2 EPOR HGF MET
6
Show member pathways
13.02 EGFR EPHB2 EPOR HGF MAPK14 MET
7
Show member pathways
13.01 CSF3 EGFR EPHB2 EPOR HGF MAPK14
8
Show member pathways
12.89 CSF3 ECE1 EGFR EPHB2 EPOR HGF
9
Show member pathways
12.84 EGFR EPHB2 HGF MAPK14 MET
10
Show member pathways
12.78 EGFR EPHB2 EPOR MAPK14 MET
11
Show member pathways
12.75 CSF3 EGFR EPOR HGF MET
12
Show member pathways
12.73 EGFR HGF MAPK14 MET
13
Show member pathways
12.68 EGFR EPOR MAPK14 MET
14 12.67 EGFR EPOR HGF MET
15 12.57 EGFR HGF MAPK14 MET
16
Show member pathways
12.44 CNR1 EGFR HGF MAPK14 MET
17
Show member pathways
12.19 HGF MAPK14 MET
18
Show member pathways
12.19 CSF3 EGFR EPOR
19 12.09 EGFR HGF MAPK14 MET
20 11.95 EGFR EPHB2 MET
21 11.89 GATA4 HGF MET
22 11.88 EGFR HGF MET
23
Show member pathways
11.68 EGFR HGF MET
24 11.32 CSF3 HGF MET
25
Show member pathways
11.23 EGFR HGF MET
26 11.19 EGFR EPOR GATA4 MAPK14
27 11.15 EGFR MET
28 11.15 EGFR HGF MET
29 11.07 EGFR EPOR
30 11.06 CSF3 HGF MAPK14
31 11.03 GATA4 MAPK14
32 10.96 EGFR HGF MET
33 10.83 HGF MET
34 10.81 EGFR HGF MET
35 10.07 CSF3 DES EGFR EPHB2 EPOR HGF

GO Terms for Doxorubicin Induced Cardiomyopathy

Cellular components related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.17 CSF3 EGFR EPHB2 EPOR HGF MAPK14

Biological processes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.88 CSF3 EGFR GATA4 HGF MAPK14 MET
2 protein phosphorylation GO:0006468 9.83 EGFR EPHB2 MAPK14 MET
3 MAPK cascade GO:0000165 9.73 EGFR HGF MAPK14 MET
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 EGFR EPHB2 MET
5 phosphatidylinositol phosphorylation GO:0046854 9.63 EGFR HGF MET
6 positive chemotaxis GO:0050918 9.54 HGF MET
7 learning or memory GO:0007611 9.54 CNR1 EGFR EPHB2
8 axonal fasciculation GO:0007413 9.51 CNR1 EPHB2
9 hepatocyte growth factor receptor signaling pathway GO:0048012 9.48 HGF MET
10 peptidyl-tyrosine phosphorylation GO:0018108 9.46 EGFR EPHB2 HGF MET
11 negative regulation of autophagy GO:0010507 9.43 GATA4 HGF MET
12 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.32 HGF MET
13 positive regulation of protein kinase B signaling GO:0051897 9.26 CSF3 EGFR HGF MET
14 cell morphogenesis GO:0000902 8.92 EGFR EPHB2 HGF MAPK14

Molecular functions related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.73 EGFR EPHB2 MAPK14 MET
2 identical protein binding GO:0042802 9.73 DES EGFR EPHB2 EPOR HGF MET
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.58 EGFR HGF MET
4 protein phosphatase binding GO:0019903 9.54 EGFR MAPK14 MET
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR HGF MET
6 NFAT protein binding GO:0051525 9.16 GATA4 MAPK14
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHB2 MET
8 protein tyrosine kinase activity GO:0004713 8.92 EGFR EPHB2 HGF MET

Sources for Doxorubicin Induced Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....